On November 4, 2009, Bioject Medical Technologies Inc. (“Bioject”) issued a press release announcing a net loss allocable to common shareholders of $0.2 million, or $0.01 per share, on revenues of $1.5 million for its third quarter ended September 30, 2009. Bioject also announced a net loss allocable to common shareholders of $0.7 million, or $0.04 per share, on revenues of $5.2 million for the nine-month period ended September 30, 2009. A copy of the press release is attached as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
| (d) | Exhibits |
The following exhibit is furnished herewith and this list is intended to constitute the exhibit index:
| 99.1 | Press release dated November 4, 2009 announcing Bioject Medical Technologies Inc.’s results for its third quarter ended September 30, 2009. |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: November 4, 2009 | BIOJECT MEDICAL TECHNOLOGIES INC. | |||
| (Registrant) | ||||
| /S/ CHRISTINE M. FARRELL | ||||
| Christine M. Farrell | ||||
| Vice President of Finance | ||||
| (Principal Financial and Accounting Officer) | ||||
2